These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 32328061)

  • 21. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
    Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
    Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimized clonotypic analysis of T-cell receptor repertoire in immune reconstitution.
    Packer AN; Muraro PA
    Exp Hematol; 2007 Mar; 35(3):516-21. PubMed ID: 17309832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.
    Suessmuth Y; Mukherjee R; Watkins B; Koura DT; Finstermeier K; Desmarais C; Stempora L; Horan JT; Langston A; Qayed M; Khoury HJ; Grizzle A; Cheeseman JA; Conger JA; Robertson J; Garrett A; Kirk AD; Waller EK; Blazar BR; Mehta AK; Robins HS; Kean LS
    Blood; 2015 Jun; 125(25):3835-50. PubMed ID: 25852054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis.
    Ruder J; Docampo MJ; Rex J; Obahor S; Naghavian R; Müller AMS; Schanz U; Jelcic I; Martin R
    Sci Transl Med; 2022 Nov; 14(669):eabq1693. PubMed ID: 36322629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
    Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
    BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation.
    Link CS; Eugster A; Heidenreich F; Rücker-Braun E; Schmiedgen M; Oelschlägel U; Kühn D; Dietz S; Fuchs Y; Dahl A; Domingues AM; Klesse C; Schmitz M; Ehninger G; Bornhäuser M; Schetelig J; Bonifacio E
    Clin Exp Immunol; 2016 Jun; 184(3):389-402. PubMed ID: 26800118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometric analysis of TCR Vβ repertoire in patients with 22q11.2 deletion syndrome.
    McLean-Tooke A; Barge D; Spickett GP; Gennery AR
    Scand J Immunol; 2011 Jun; 73(6):577-85. PubMed ID: 21323691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
    Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
    Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update.
    Lutter L; Spierings J; van Rhijn-Brouwer FCC; van Laar JM; van Wijk F
    Front Immunol; 2018; 9():767. PubMed ID: 29731752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4
    Marusina AI; Ono Y; Merleev AA; Shimoda M; Ogawa H; Wang EA; Kondo K; Olney L; Luxardi G; Miyamura Y; Yilma TD; Villalobos IB; Bergstrom JW; Kronenberg DG; Soulika AM; Adamopoulos IE; Maverakis E
    J Autoimmun; 2017 Feb; 77():76-88. PubMed ID: 27894837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Ruder J; Rex J; Obahor S; Docampo MJ; Müller AMS; Schanz U; Jelcic I; Martin R
    Front Immunol; 2021; 12():794077. PubMed ID: 34975899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.
    Sweeney ME; Slusser JG; Lynch SG; Benedict SH; Garcia SL; Rues L; LeVine SM
    Int Immunopharmacol; 2011 Nov; 11(11):1796-801. PubMed ID: 21807124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor CD4 T Cell Diversity Determines Virus Reactivation in Patients After HLA-Matched Allogeneic Stem Cell Transplantation.
    Ritter J; Seitz V; Balzer H; Gary R; Lenze D; Moi S; Pasemann S; Seegebarth A; Wurdack M; Hennig S; Gerbitz A; Hummel M
    Am J Transplant; 2015 Aug; 15(8):2170-9. PubMed ID: 25873100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive assessment of T-cell repertoire following autologous hematopoietic stem cell transplantation for treatment of type 1 diabetes using high-throughput sequencing.
    Zhang J; Hu M; Wang B; Gao J; Wang L; Li L; Chen S; Cui B; Gu W; Wang W; Ning G
    Pediatr Diabetes; 2018 Nov; 19(7):1229-1237. PubMed ID: 30022578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.